Waldencast plc (WALD)
| Market Cap | 216.98M |
| Revenue (ttm) | 274.56M |
| Net Income (ttm) | -201.81M |
| Shares Out | 128.39M |
| EPS (ttm) | -1.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,510 |
| Open | 1.700 |
| Previous Close | 1.700 |
| Day's Range | 1.690 - 1.840 |
| 52-Week Range | 1.450 - 3.540 |
| Beta | -0.47 |
| Analysts | Strong Buy |
| Price Target | 4.30 (+154.44%) |
| Earnings Date | Nov 24, 2025 |
About WALD
Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company operates through two segments, Obagi Medical and Milk Makeup. It offers skin care products to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and protect and enhance skin tone and texture; cosmetics; and other beauty products. In addition, the company provides foundation, concealer, primer, blush, setting spray, and bronzer categories, as w... [Read more]
Analyst Forecast
According to 5 analysts, the average rating for WALD stock is "Strong Buy." The 12-month stock price target is $4.3, which is an increase of 154.44% from the latest price.
News
Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices Sc...
Obagi Medical and It's a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
It's a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing ne...
Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic prac...
Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices DermFx selected as a ...
Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs Moxie selected as a leading aesthetic p...
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips The dermatologist-tested duo pairs gentle chemical resurfacing with dai...
Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
VIO Med Spa selected as a key med spa franchise partner for its commitment to clinical excellence, innovation, and nationwide scalable aesthetic care VIO Med Spa selected as a key med spa franchise pa...
Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Next Health selected as a leading wellness and longevity partner given its innovative approach to personalized aesthetics and health optimization Next Health selected as a leading wellness and longevi...
UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers Alpha selected as the first Medspa platform partner given their commi...
Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers Alpha selected as the first Medspa platform partner given their commi...
CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices Platinum selected as the first dermatology plat...
Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler
Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare
Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting
Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation
Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its righ...
Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates
First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on Novemb...
Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Ha...
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market U.S. Launch...
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S.
Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Waldencast plc WALD will release earnings results for the second quarter after the closing bell on Monday, Aug. 18.
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics...
Waldencast: Learning To Grow Hurts Sometimes
Waldencast is a fast-growing beauty company with strong brands (Milk Makeup, Obagi), but faces margin pressure and negative earnings due to high SG&A and debt. Recent revenue growth remains solid, but...
Waldencast plc (WALD) Q1 2025 Earnings Call Transcript
Waldencast plc (NASDAQ:WALD) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Allison Malkin - Partner ICR, Investor Relations Michel Brousset - Founder & Chief Executive...
Waldencast Reports Q1 2025 Financial Results
Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA
Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast
LONDON, May 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its First Quarter Fiscal 2025 confere...
Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream
A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion